The impact of multiple malignancies on patients with bladder carcinoma: A population-based study using the SEER database

Advances in Urology

Volumn , Issue , 2009, Pages

  Scherr, Douglas S ^a   Ehrlich, Joshua R ^a   Schwartz, Michael J ^a   Ng, Casey K ^a   Kauffman, Eric C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74849117182     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2009/406965     Document Type: Article

References (17)

1. Fraumeni J. F. Jr., Curtis R. E., Edwards B. K., Tucker M. A., Curtis R. E., Friedman D. M., Ron E., Introduction New Malignancies Among Cancer Survivors: SEER Cancer Registries, 19732000 2006 Bethesda, Md, USA National Cancer Institute 1 8. NIH Publ. No. 05-5302
2. Mariotto A. B., Rowland J. H., Ries L. A. G., Scoppa S., Feuer E. J., Multiple cancer prevalence: a growing challenge in long-term survivorship Cancer Epidemiology Biomarkers and Prevention 2007 16 3 566 571
3. Lamm D. L., Blumenstein B. A., Crissman J. D., Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study Journal of Urology 2000 163 4 1124 1129
4. Herr H. W., Schwalb D. M., Zhang Z.-F., Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial Journal of Clinical Oncology 1995 13 6 1404 1408
5. Bisiaux A., Thiounn N., Timsit M.-O., Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette-Guerin therapy in patients with superficial bladder cancer Journal of Urology 2009 181 4 1571 1580
6. Gan Y.-H., Mahendran R., James K., Lawrencia C., Esuvaranathan K., Evaluation of lymphocytic responses after treatment with bacillus Calmette-Guerin and interferon- 2b for superficial bladder cancer Clinical Immunology 1999 90 2 230 237
7. Klein G., Klein E., Surveillance against tumorsis it mainly immunological? Immunology Letters 2005 100 1 29 33
8. Ng A. K., Travis L. B., Subsequent malignant neoplasms in cancer survivors Cancer Journal 2008 14 6 429 434
9. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape Nature Immunology 2002 3 11 991 998
10. Levine L. A., Richie J. P., Urological complications of cyclophosphamide Journal of Urology 1989 141 5 1063 1069
11. Boorjian S., Cowan J. E., Konety B. R., Bladder cancer incidence and risk factors in men with prostate cancer: results from cancer of the prostate strategic urologic research endeavor Journal of Urology 2007 177 3 883 888
12. Sandhu J. S., Vickers A. J., Bochner B., Donat S. M., Herr H. W., Dalbagni G., Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer BJU International 2006 98 1 59 62
13. Bostrom P. J., Soloway M. S., Manoharan M., Ayyathurai R., Samavedi S., Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy Journal of Urology 2008 179 1 91 95
14. Moon K., Stukenborg G. J., Keim J., Theodorescu D., Cancer incidence after localized therapy for prostate cancer Cancer 2006 107 5 991 998
15. Pabla N., Dong Z., Cisplatin nephrotoxicity: mechanisms and renoprotective strategies Kidney International 2008 73 9 994 1007
16. de Forni M., Armand J.-P., Cardiotoxicity of chemotherapy Current Opinion in Oncology 1994 6 4 340 344
17. Duchateau C. S. J., Stokkel M. P. M., Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival Chest 2005 127 4 1152 1158